All News

The technology is part of a larger platform that provides a variety of AI-powered services.

John Hood, CEO, Endeavor BioMedicines discusses partnering with advocacy groups to increase awareness of clinical trials for idiopathic pulmonary fibrosis.

Acceptance of the Biologics License Application for subcutaneous Leqembi is based on results from the Clarity AD open-label extension and modeling of observed data in patients with Alzheimer disease.

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.

The association also named Jim Weiss as honorable mentor and Rebecca Vermeulen as its STAR recipient.

The new digital ecosystem offers scalable and flexible environment for clinical development.

Organizations including Gilead, Eli Lilly, and AbbVie announced a number of deals addressing inflammatory diseases, multiple myeloma, and other disease areas.

Under terms of the deal, GSK will also acquire IDRX-42, a tyrosine kinase inhibitor designed to treat both primary and secondary KIT mutations in patients with gastrointestinal stromal tumors.

Acquisition includes Caplyta, a once-daily oral therapy approved for schizophrenia and bipolar depression.

Company leadership urged members and employees to stay safe and follow evacuation orders.

San Francisco Police cancel time off requests to increase security at the J.P. Morgan Healthcare Conference after the recent murder of UnitedHealth Group CEO Brian Thompson.

Priority Review was based on results from the Phase III Vivacity-MG3 study of nipocalimab in patients with generalized myasthenia gravis.

Dan Monahan will serve in the role as the drug goes through Phase III trials.

‘Shape Shifting’ is a creator-led series that focuses on the scientific and cultural impact of GLP-1s.

Abrysvo and Arexvy will now be required to come with labeling that includes a warning about a potential increased risk of Guillain-Barré Syndrome.

The campaign will include patient stories, education resources, and is being held in partnership with the Glaucoma Research Foundation.

Mary Kosinski joined the firm as global managing director for the sector, along with other leadership additions.

This acquisition will help generate data from over four million members of MyHealthTeams’ opted-in patient universe.

Both companies have produced AI-powered technology that improves data collection and analysis.

The future is bright with AI-powered innovations, but migration presents significant risks, including data loss, increased costs, and disruption to business operations.

The addition of Peregrine builds on Klick’s market access execution capabilities.

Fast Track designation was based on results from a Phase II study, which demonstrated that VGT-309 was safe, well-tolerated, and enhanced tumor visualization in lung cancer patients.

Breakthrough Therapy Designation for GSK5764227 was based on data from the ARTEMIS-002 Phase II trial, which demonstrated promising efficacy and safety in 42 osteosarcoma patients.

Guidance marks the regulatory body’s first on artificial intelligence applications in drug and biological product development.

The designation marks VGA039 as the first drug candidate to receive FDA Fast Track designation for von Willebrand disease.

Data from the Phase III trial program found that AXS-05 demonstrated statistically significant efficacy in treating Alzheimer disease agitation.

John Hood, CEO, Endeavor BioMedicines discusses a potential timeline on availability of ENV-101 for patients with IPF and further validation of the treatment's safety profile.

The campaign is focused on the drug’s ability to fight hunger cravings.